Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017

世界のプロティンエンジニアリング(蛋白質工学)関連市場

◆タイトル:Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017
◆商品コード:BT 1358
◆調査・発行会社:MarketsandMarkets
◆発行日:2013年3月
◆ページ数:148
◆レポート形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single userUSD5,650 ⇒換算¥627,150見積依頼/購入/質問フォーム
Multi User(~5名まで)USD6,650 ⇒換算¥738,150見積依頼/購入/質問フォーム
Corporate licence(社内共有可)USD8,150 ⇒換算¥904,650見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界のプロティンエンジニアリング(蛋白質工学)関連市場"について調査・分析し、イントロダクション、エグゼクティブサマリー、市場の成長要因、阻害要因、市場の機会と課題、バリューチェーン分析、市場の動態、パイプライン分析、技術別分析、製品別分析、用途別分析、地域別分析、市場規模及び予測、競争状況、市場シェア分析、新製品発売、主要企業(ベンダー)分析等の情報をお届けいたします。

Proteins exhibit high specificity and less immunogenicity and are widely used as therapeutic agents in the treatment of various disorders and diseases. There are more than 200 protein-based products currently being marketed; 90% of them are used as therapeutics. In order to improve their clinical potential, second generation recombinants are being developed, each exhibiting improved efficiency and potency depending on their applications.

The global protein engineering technologies market (2012-2017) report analyses the market by technology, products, applications, and geography. It also includes recent technology trends, patents, and funding analysis. In addition, it also covers factors driving and restraining the growth of the market and market scenario in the U.S., Europe, Asia, and Rest of the World (RoW).

The protein engineering market is driven by the need for drugs with improved efficiency and specificity, technological capabilities, rise of antibody based drugs, and steady growth in the therapeutic market. With growing incidences of cancer, autoimmune disorders, and infectious disease, spurt of new opportunities for growth of the market is expected by the end of this decade. However, development costs, stringent regulatory issues, and risk of failure of the drug in the testing phase restraints the growth of the market. Further, the availability of generics and patent infringements is posing a threat to the market.

The global protein engineering market is expected to grow at a CAGR of 10.9%; this growth is majorly fuelled by monoclonal antibodies, which is the fastest growing segment in therapeutics. The use of monoclonal antibodies in therapeutics such as oncology, auto immune and inflammatory diseases are expected to increase during the forecast period. Chinas growing interest in research of monoclonal antibodies is expected to increase market share further. The market is likely to face competition from the entry of generics; however, with many therapeutic proteins in the pipeline, the market is expected to grow exponentially. Insulin analogs, which are more efficient than the recombinant insulin, are also a contributing factor for growth of the market. Diagnostics is another segment in focus; monoclonal antibodies are being used extensively in diagnostics and in assays for research.

The report also profiles leading participants of the industry with their recent developments and other strategic industry activities. These include Genentech (U.S.), Amgen (U.S.), Roche (Switzerland), Eli Lilly (U.S.), Novartis (Switzerland), GlaxoSmithKline (U.K.), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Merck (U.S.), Pfizer (U.S.), Sanofi (France), Affymax (U.S.), Biogen Idec, (U.S.), Medimmune (U.S.) Affimed (Germany), and Obodies (New Zealand).

Scope of the Report

This technical report categorizes the market for protein engineering by geography, applications, products, and technology, forecasting the market revenue by analyzing current and future trends in therapeutics and diagnostics.These markets are broken down into segments and sub-segments, providing exhaustive value analysis for 2010, 2011 and 2012, as well as forecast up to 2017. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.

Global Protein engineering, by Technology

Sequence modification
Glycosylation
Pegylation
Display technologies
Humanization technology
Hybrid technology
Transgenic mice
Global Protein engineering, by Product

mAb
Insulin
Others
EPO
Diagnostics
Research
Geographic Analysis

North America
U.S.
Canada
Europe
U.K.
France
Germany
Italy
Asia
Indonesia
India
China
South Korea
Rest of the World (RoW)
Japan
Australia

【レポートの目次】

Table Of Content
1 Introduction (Slide No. 18 – 23)
1.1 Key Take- Aways
1.2 Assumptions
1.3 Report Scope
1.4 Research Methodology
1.5 Key Data Points From Primary And Secondary Sources

2 Executive Summary (Slide No. 24 – 27)

3 Protein Engineering Technologies – Landscape Analysis (Slide No. 28 – 45)
3.1 Technology – Introduction
3.2 Technology – Evolution
3.3 Market Segmentation
3.4 Protein And Antibody Engineering Technologies – Overview
3.4.1 Sequence Modification
3.4.2 Glycosylation
3.4.3 Pegylation
3.4.4 Display Technologies
3.4.5 Humanization Technology
3.4.6 Hybrid Technology
3.4.7 Production Systems
3.4.8 Mapping Of Protein Production Systems
3.4.9 Emerging Production Systems
3.5 Protein Engineering – Technology Value Chain Analysis

4 Applications (Slide No. 46 – 54)
4.1 Therapeutic Development – Overview
4.1.1 Insulin Analogs
4.1.2 Monoclonal Antibodies
4.1.3 Therapeutic Development – Erythropoietin & Others
4.2 Diagnostics
4.3 Research – Meganuclease Engineering / ZFP & TALENS Engineering

5 Market Landscape Analysis (Slide No. 55 – 92)
5.1 Global Protein Engineering Market Forecast
5.1.1 Introduction
5.1.2 Global Market Forecast, By Geography
5.1.3 Global Market Forecast, By Product
5.1.4 Global Market Forecast, By Application
5.1.5 Global Market Forecast, By Technology
5.2 Market Dynamics – Overview
5.2.1 Drivers – Description
5.2.2 Drivers’ Impact – Timeline
5.2.3 Restraints – Description
5.2.4 Restraints Impact – Timeline
5.2.5 Opportunities – Description
5.2.6 Threats – Description
5.2.7 Pestle Analysis
5.3 Market Segmentation, By Product
5.3.1 Insulin Analogs
5.3.1.1 Insulin Analog Market
5.3.1.2 Insulin Analog Market, By Geography
5.3.1.3 Market Share Analysis
5.3.2 Modified EPO
5.3.2.1 Modified EPO Market
5.3.2.2 Modified EPO Market, By Geography
5.3.3 Monoclonal Antibodies (MAB)
5.3.3.1 Monoclonal Antibodies Market
5.3.3.2 Monoclonal Antibodies Market, By Geography
5.3.3.3 Monoclonal Antibodies Market, By Application
5.3.3.4 Major Products In The Market
5.4 Other Proteins
5.4.1 Other Proteins Market
5.4.2 Other Proteins Market, By Geography
5.4.3 Diagnostic Proteins, By Geography

6 Geographic Analysis (Slide No. 93 – 100)
6.1 North America
6.2 Europe
6.3 Asia
6.4 Row

7 Technology And Product Portfolio (Slide No. 101 – 105)
7.1 Proprietary Technology Platforms
7.2 Product Pipeline Analysis Of Key Players

8 Competitive Landscape (Slide No. 106 – 111)
8.1 Introduction
8.2 Porter’s Five Force Analysis
8.3 Mergers & Acquisitions, 2009 – 2012
8.4 Partnerships & Collaborations, 2012 – 2013
8.5 New Product Launch, 2010 – 2012

9 Analyst Insights And Recommendation (Slide No. 112 – 114)
9.1 Strategic Recommendations

10 Company Profiles (Slide No. 115 – 146)
10.1 Genentech, Inc.
10.2 Amgen, Inc.
10.3 Biogen Idec, Inc.
10.4 Novartis Ag
10.5 Glaxo Smithkline Plc
10.6 Eli Lilly & Co
10.7 Bristol Myers Squibb Co.
10.8 Johnson & Johnson
10.9 Merck & Co., Inc.
10.10 Sanofi
10.11 Pfizer, Inc.
10.12 Regeneron Pharmaceuticals, Inc.
10.13 Eleven Biotherapeutics (U.S.)
10.14 Toolgen, Inc. (Korea)
10.15 Dna2.0, Inc. (U.S.)
10.16 Avidbiotics Corp. (U.S.)
10.17 Sigma-Aldrich Corp. (U.S.)
10.18 Xencor Inc.
10.19 Morphosys

List Of Tables (11 Tables)

Table - 1 Global Protein Engineering Market Revenue, 2012 - 2017 ($Billion)
Table - 2 Global Market, By Geography, 2012 - 2017 ($Billion)
Table - 3 Global Market, By Product, 2012 - 2017 ($Billion)
Table - 4 Global Market, By Application, 2012 - 2017 ($Billion)
Table - 5 Global Market, By Technology, 2012 - 2017 ($Billion)
Table - 6 Insulin Analogs Market, By Geography, 2012 - 2017 ($Billion)
Table - 7 Modified Epo Market, By Geography, 2012 - 2017 ($Billion)
Table - 8 MAB Market, By Geography, 2012 - 2017 ($Billion)
Table - 9 MAB Market, By Application, 2012 - 2017 ($Billion)
Table - 10 Other Proteins Market, By Geography, 2012 - 2017 ($Billion)
Table - 11 Diagnostic Proteins Market, By Geography, 2012 - 2017 ($Billion)


List Of Figure (44 Figures)

Fig - 1 Global Protein Engineering Market, 2012 - 2017 ($Billion)
Fig - 2 Global Market, 2012 - 2017 ($Billion)
Fig - 3 Global Market, By Geography, 2012 (%)
Fig - 4 Growth Rate, By Geography, 2012 - 2017
Fig - 5 Global Protein Engineering Market By Geography, 2012 - 2017 ($Billion)
Fig - 6 Global Protein Engineering Market, By Product, 2012 (%)
Fig - 7 Growth Rate, By Product, 2012 - 2017
Fig - 8 Global Market, By Product, 2012 - 2017 ($Billion)
Fig - 9 Global Protein Engineering Market, By Application, 2012 (%)
Fig - 10 Growth Rate, By Application, 2012 - 2017
Fig - 11 Global Market, By Application, 2012 - 2017 ($Billion)
Fig - 12 Global Protein Engineering Market, By Technology, 2012 (%)
Fig - 13 Growth Rate, By Technology, 2012 - 2017
Fig - 14 Global Market, By Technology, 2012 - 2017 ($Billion)
Fig - 15 Market Share Analysis
Fig - 16 Insulin Analogs Market, By Geography, 2012
Fig - 17 Insulin Analogs Market, By Geography, 2012 - 2017 ($Billion)
Fig - 18 Market Share Analysis, Key Players, 2012
Fig - 19 Market Share Analysis Of Epo, By Product, 2012
Fig - 20 Modified EPO Market, By Geography, 2012
Fig - 21 Modified EPO Market, By Geography, 2012 - 2017 ($Billion)
Fig - 22 Market Share Analysis Of Engineered Therapeutic Proteins, By Product, 2012
Fig - 23 MAB Market, By Geography, 2012
Fig - 24 MAB Market, By Geography, 2012 - 2017 ($Billion)
Fig - 25 MAB Market,By Application, 2012
Fig - 26 MAB Market, By Application, 2012 - 2017 ($Billion)
Fig - 27 Market Share Analysis Of Other Proteins, 2012
Fig - 28 Other Proteins Market, By Geography, 2012
Fig - 29 Other Proteins Market, By Geography, 2012 - 2017 ($Billion)
Fig - 30 Diagnostic Proteins Market, By Geography, 2012
Fig - 31 Diagnostic Proteins Market, By Geography, 2012 - 2017 ($Billion)
Fig - 32 Product Pipeline Of Key Players
Fig - 33 Growth Strategies
Fig - 34 Amgen, Inc., Total Revenue
Fig - 35 Biogen Idec, Inc., Total Revenue
Fig - 36 Novartis Ag, Total Revenue
Fig - 37 Glaxo Smithkline Plc, Total Revenue
Fig - 38 Eli Lilly & Co., Total Revenue
Fig - 39 Bristol Myers Squibb Co., Total Revenue
Fig - 40 Johnson & Johnson , Total Revenue
Fig - 41 Merck & Co., Inc., Total Revenue
Fig - 42 Sanofi , Total Revenue
Fig - 43 Pfizer, Inc., Total Revenue
Fig - 44 Regeneron Pharmaceuticals, Inc. , Total Revenue

★調査レポート[世界のプロティンエンジニアリング(蛋白質工学)関連市場] ( Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017 / BT 1358) 販売に関する免責事項
[世界のプロティンエンジニアリング(蛋白質工学)関連市場] ( Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017 / BT 1358) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆